Generic vs. Compounded GLP-1s: What's Actually Generic in the US

As of October 2026, the GLP-1 drugs with FDA-approved generics in the US are exenatide (generic Byetta) and liraglutide (generic Victoza and generic Saxenda). No generic semaglutide or tirzepatide has final FDA approval or is on the US market; FDA granted one generic semaglutide injection a tentative approval in April 2026, which does not allow it to be sold yet. Products sold as "generic semaglutide" online are either compounded drugs, which are not FDA-approved, or unapproved imports.

What "generic" actually means

In US law, a generic is not just a cheaper version of a medicine. It is a product FDA has approved under an abbreviated new drug application (ANDA) after reviewing evidence that it matches a brand-name reference drug. According to FDA, the generic must have the same active ingredient, the same strength and dosage form, and the same route of administration, and it must be bioequivalent to the brand. FDA also inspects the manufacturing plants (FDA Generic Drug Facts).

A compounded drug works differently. A state-licensed pharmacy (under section 503A) or an FDA-registered outsourcing facility (under section 503B) prepares it, often from bulk active ingredient. FDA states that "compounded drugs are not FDA-approved" and that it does not review them "to evaluate their safety, effectiveness, or quality before they reach patients" (FDA Compounding Laws and Policies).

Source: FDA Generic Drug Facts; FDA Compounding Laws and Policies; 21 U.S.C. 353a.

Which GLP-1s have US generics

Source: FDA 2024 First Generic Drug Approvals and 2025 First Generic Drug Approvals. These lists show first generics only; other companies may hold later approvals.

Amneal described its exenatide pens as "one of the first generic GLP-1 injectables to be approved in the U.S." (Amneal, Nov. 21, 2024). Hikma said it would launch its generic Victoza immediately upon approval (Hikma, Dec. 2024). FDA notes on its approval lists that an approved generic is not always on the market on its approval date.

Liraglutide and exenatide are different molecules from semaglutide and tirzepatide, with their own labels and dosing schedules, so a generic of one does not substitute for the others. Whether one fits you is a decision for your prescriber.

When could generic semaglutide launch in the US?

No public date exists. What is public is the patent and exclusivity record. FDA's Orange Book lists patent 8,129,343, the semaglutide compound patent, as expiring on December 5, 2031 for Ozempic. Other listed Ozempic patents run as late as June 21, 2033, and an indication-specific exclusivity runs to January 28, 2028 (FDA Orange Book, Ozempic).

FDA has taken one step toward a generic. On April 10, 2026, it announced its first tentative approval of a generic semaglutide injection, an application from Apotex. A tentative approval means FDA has finished its review but the product cannot be marketed while patent or exclusivity barriers remain, so it is not available to patients (HCPLive, April 2026). A May 2026 report summarized the expectation that Americans are unlikely to see generic semaglutide before the end of 2031 (Becker's Hospital Review, May 14, 2026).

And tirzepatide?

Tirzepatide is further away. For Zepbound, the Orange Book lists new chemical entity exclusivity through May 13, 2027, a drug substance patent (9,474,780) through May 13, 2036, and drug product and use patents running into 2039 (FDA Orange Book, Zepbound). Patents can be challenged or settled, so these are listings, not guaranteed launch dates. FDA itself notes that listings alone don't define everything a brand company may assert.

Where compounding fits, and why "generic" is the wrong word

Section 503A generally bars a pharmacy from compounding regularly or in inordinate amounts any drug that is "essentially a copy" of a commercially available product (21 U.S.C. 353a). That is close to the opposite of the generic standard: a generic must match the brand, while a compounded product generally must not be a copy of one unless a prescriber documents a significant difference for an individual patient.

FDA's April 1, 2026 statement explains that it may treat a compounded product as essentially a copy if it has the same active ingredient in a "same, similar or an easily substitutable strength" and the same route as an approved product. FDA also said that, "at this time," it does not intend to act against a 503A compounder that fills four or fewer prescriptions of such a product in a calendar month. For 503B outsourcing facilities, FDA said semaglutide and tirzepatide "do not currently appear" on either the 503B bulks list or the shortage list (FDA, April 1, 2026). In a Federal Register notice published May 1, 2026, FDA proposed not to include semaglutide, tirzepatide, or liraglutide on the 503B bulks list (Federal Register, May 1, 2026). FDA extended the comment period to July 30, 2026, and no final determination had been published as of the notices reviewed here (Federal Register, June 26, 2026).

What generic liraglutide means for compounded liraglutide

FDA's 2018 guidance on essentially copies treats a marketed drug as "commercially available" unless it is discontinued or on FDA's drug shortage list with a status of "currently in shortage" (FDA guidance, Jan. 2018). With approved generic liraglutide now marketed, the question for any compounded liraglutide is whether liraglutide is listed as currently in shortage. As of October 18, 2026, FDA's drug shortage database still listed liraglutide injection as "Currently in Shortage" (FDA Drug Shortages). That status can change at any time, so check the database before assuming either way.

The same guidance says a lower price is not a "significant difference" that justifies compounding a copy. Cost is a real concern for patients, but it is not the legal test.

Worked example

Suppose a reader searches "generic semaglutide" and lands on a page offering "generic semaglutide, same as Ozempic" for a monthly fee. Here is how to read that offer:

1. Is there an FDA-approved generic on the market? No. As of October 2026 FDA has granted only a tentative approval for one generic semaglutide injection, which cannot be marketed yet, and the Orange Book compound patent runs to December 2031.
2. So what is being sold? Most likely a compounded product or an unapproved import. Ask which pharmacy dispenses it and whether it is a 503A or 503B facility.
3. Is "same as Ozempic" accurate? No. A compounded product hasn't been shown equivalent to Ozempic, and FDA's policy is that compounders generally may not make copies.
4. What should she ask next? Whether the prescriber is documenting a patient-specific significant difference, and what the pharmacy's license and testing look like.

This example is illustrative and does not describe any real company.

Questions to ask your prescriber or pharmacy

• Is this an FDA-approved product, an FDA-approved generic, or a compounded drug?
• If compounded, which pharmacy makes it, and is it a 503A pharmacy or a 503B outsourcing facility?
• If it is offered as "generic," what ANDA or brand reference does it rely on?
• Would an approved generic (such as liraglutide) be appropriate for me instead, and would insurance cover it?
• What patient-specific reason supports a compounded version over an approved product?

Where this guide stops

This article explains US regulatory categories and public patent listings. It does not predict litigation outcomes, cover every generic approval after the first, or address insurance coverage. It is not medical or legal advice. Patent dates can change through litigation, settlements, or extensions.

Compare available care options

Whatever you consider, verify the prescriber's and pharmacy's credentials and the terms yourself. A listing is not a recommendation or a prescription.

Disclosure: we may earn a commission if you use a listed provider. Compensation does not establish a provider's safety, legitimacy, or value.

Sources

1. FDA: Generic Drug Facts
2. FDA: Compounding Laws and Policies
3. FDA: 2024 First Generic Drug Approvals
4. FDA: 2025 First Generic Drug Approvals
5. Amneal: FDA approval of exenatide (Nov. 21, 2024)
6. Hikma: FDA approval and launch of generic Victoza (Dec. 2024)
7. FDA Orange Book: Ozempic (N209637) patents and exclusivity
8. HCPLive: FDA gives tentative approval of ANDA for generic semaglutide injection (April 2026)
9. Becker's Hospital Review: Why generic Ozempic could be delayed in the US
10. FDA Orange Book: Zepbound (N217806) patents and exclusivity
11. 21 U.S.C. 353a (FD&C Act section 503A), Cornell LII
12. FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (updated April 1, 2026)
13. Federal Register: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (May 1, 2026)
14. Federal Register: Extension of Comment Period (June 26, 2026)
15. FDA Drug Shortages: Liraglutide Injection
16. FDA guidance: Compounded drug products that are essentially copies of a commercially available drug product under section 503A (Jan. 2018)

Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.